Form 8-K - Current report:
SEC Accession No. 0001213900-25-018776
Filing Date
2025-02-28
Accepted
2025-02-28 16:15:33
Documents
15
Period of Report
2024-12-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0232284-8k_longeveron.htm   iXBRL 8-K 25807
2 PRESS RELEASE ISSUED BY THE COMPANY ON FEBRUARY 28, 2025 ea023228401ex99-1_long.htm EX-99.1 81718
3 GRAPHIC ex99-1_001.jpg GRAPHIC 9137
  Complete submission text file 0001213900-25-018776.txt   308265

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lgvn-20241231.xsd EX-101.SCH 3021
5 XBRL LABEL FILE lgvn-20241231_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lgvn-20241231_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0232284-8k_longeveron_htm.xml XML 3799
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40060 | Film No.: 25690410
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)